Unmatched sample baseline characteristics according to treatment of the first bleeding episode (bypassing agent vs FVIII or DDAVP and rFVIIa vs aPCC)
| Variable . | Bypassing agent, median (IQR) . | FVIII or DDAVP, median (IQR) . | P* . | rFVIIa, median (IQR) . | aPCC, median (IQR) . | P† . |
|---|---|---|---|---|---|---|
| Patients, n | 219 | 69 | 159 | 60 | ||
| Age, y | 73.0 (15.0-92.0) | 73.0 (13.0-104.0) | .94 | 73.0 (15.0-91.0) | 76.5 (24.0-92.0) | .02 |
| Sex, n (%) | .07 | .06 | ||||
| Female | 109 (49.7) | 26 (37.7) | 73 (45.9) | 36 (60.0) | ||
| Male | 110 (50.8) | 43 (62.3) | 86 (54.1) | 24 (40.0) | ||
| Weight, kg | 69.0 (40.0-130.0) | 69.0 (40.0-113.0) | .92 | 69.0 (40.0-130.0) | 69.2 (44.0-107.0) | .70 |
| FVIII level, IU/dL | 1.0 (0.0-40.0) | 3.0 (0.0-34.0) | .03 | 2.0 (0.0-32.0) | 1.0 (0.0-40.0) | .13 |
| Hb, g/dL | 8.6 (3.0-15.2) | 8.8 (3.3-14.4) | .57 | 8.6 (3.0-15.2) | 8.4 (4.6-14.8) | .90 |
| Inhibitor titer, BU/mL | 15.4 (0.1-2765.0) | 8.0 (0.3-200.0) | .0003 | 15.0 (1.0-2765.0) | 17.0 (0.1-1700.0) | .99 |
| Therapy delay, days | 0.01 (0.0-0.5) | 0.01 (0.00-0.11) | .34 | 0.01 (0.00-0.27) | 0.01 (0.00-0.54) | .76 |
| Ancillary antifibrinolytic therapy, n (%) | 30 (13.7) | 20 (29.0)‡ | .0035 | 27 (17.0) | 3 (5.0) | .0215 |
| Cause of bleeding, n (%) | .715 | .08 | ||||
| Unknown | 1 | 0 | 1 | 0 | ||
| Traumatic | 46 (21.1) | 16 (23.2) | 38 (24.1) | 8 (13.3) | ||
| Spontaneous | 172 (78.9) | 53 (76.8) | 120 (75.9) | 52 (86.7) | ||
| Bleeding site, n (%) | .04 | .12 | ||||
| CNS | 5 (2.3) | 0 (0.0) | 5 (3.1) | 0 (0.0) | ||
| Deep muscle | 139 (63.4) | 32 (46.4) | 94 (59.1) | 45 (75.0) | ||
| Hemarthrosis | 6 (2.7) | 3 (4.3) | 5 (3.1) | 1 (1.7) | ||
| Mucosa | 34 (15.6) | 21 (30.5) | 30 (18.8) | 4 (6.6) | ||
| Skin | 34 (15.6) | 13 (18.8) | 24 (15.2) | 10 (16.7) | ||
| Multiple sites | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0 (0.0) | ||
| Severity of bleeding, n (%) | .031 | .31 | ||||
| Unknown | 1 | 0 | 1 | 0 | ||
| Severe | 193 (88.5) | 54 (78.2) | 142 (89.8) | 51 (85.0) | ||
| Nonsevere | 25 (11.5) | 15 (21.8) | 16 (10.1) | 9 (15.0) | ||
| Variable . | Bypassing agent, median (IQR) . | FVIII or DDAVP, median (IQR) . | P* . | rFVIIa, median (IQR) . | aPCC, median (IQR) . | P† . |
|---|---|---|---|---|---|---|
| Patients, n | 219 | 69 | 159 | 60 | ||
| Age, y | 73.0 (15.0-92.0) | 73.0 (13.0-104.0) | .94 | 73.0 (15.0-91.0) | 76.5 (24.0-92.0) | .02 |
| Sex, n (%) | .07 | .06 | ||||
| Female | 109 (49.7) | 26 (37.7) | 73 (45.9) | 36 (60.0) | ||
| Male | 110 (50.8) | 43 (62.3) | 86 (54.1) | 24 (40.0) | ||
| Weight, kg | 69.0 (40.0-130.0) | 69.0 (40.0-113.0) | .92 | 69.0 (40.0-130.0) | 69.2 (44.0-107.0) | .70 |
| FVIII level, IU/dL | 1.0 (0.0-40.0) | 3.0 (0.0-34.0) | .03 | 2.0 (0.0-32.0) | 1.0 (0.0-40.0) | .13 |
| Hb, g/dL | 8.6 (3.0-15.2) | 8.8 (3.3-14.4) | .57 | 8.6 (3.0-15.2) | 8.4 (4.6-14.8) | .90 |
| Inhibitor titer, BU/mL | 15.4 (0.1-2765.0) | 8.0 (0.3-200.0) | .0003 | 15.0 (1.0-2765.0) | 17.0 (0.1-1700.0) | .99 |
| Therapy delay, days | 0.01 (0.0-0.5) | 0.01 (0.00-0.11) | .34 | 0.01 (0.00-0.27) | 0.01 (0.00-0.54) | .76 |
| Ancillary antifibrinolytic therapy, n (%) | 30 (13.7) | 20 (29.0)‡ | .0035 | 27 (17.0) | 3 (5.0) | .0215 |
| Cause of bleeding, n (%) | .715 | .08 | ||||
| Unknown | 1 | 0 | 1 | 0 | ||
| Traumatic | 46 (21.1) | 16 (23.2) | 38 (24.1) | 8 (13.3) | ||
| Spontaneous | 172 (78.9) | 53 (76.8) | 120 (75.9) | 52 (86.7) | ||
| Bleeding site, n (%) | .04 | .12 | ||||
| CNS | 5 (2.3) | 0 (0.0) | 5 (3.1) | 0 (0.0) | ||
| Deep muscle | 139 (63.4) | 32 (46.4) | 94 (59.1) | 45 (75.0) | ||
| Hemarthrosis | 6 (2.7) | 3 (4.3) | 5 (3.1) | 1 (1.7) | ||
| Mucosa | 34 (15.6) | 21 (30.5) | 30 (18.8) | 4 (6.6) | ||
| Skin | 34 (15.6) | 13 (18.8) | 24 (15.2) | 10 (16.7) | ||
| Multiple sites | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0 (0.0) | ||
| Severity of bleeding, n (%) | .031 | .31 | ||||
| Unknown | 1 | 0 | 1 | 0 | ||
| Severe | 193 (88.5) | 54 (78.2) | 142 (89.8) | 51 (85.0) | ||
| Nonsevere | 25 (11.5) | 15 (21.8) | 16 (10.1) | 9 (15.0) | ||
P values refer to Pearson χ2 or Mann-Whitney U test for the comparison between bypassing agent and FVIII or DDAVP.
P values refer to Pearson χ2 or Mann-Whitney U test for the comparison between rFVIIa and aPCC.
A total of 13 of 55 patients (23.6%) treated with FVIII received ancillary antifibrinolytic treatment; 7 of 14 (50%) of patients treated with DDAVP also received antifibrinolytics.